Table 2.
Risk of Incident Dementia per year of exposure to ACE inhibitors (as a class) and by blood brain barrier crossing status of the ACE inhibitor. The reference group is users of other antihypertensive drugs in both analyses.
| All ACE inhibitors | Centrally Active ACE inhibitors |
Non-Centrally Active ACE inhibitors |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Model | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value |
| Unadjusted | 1.01 | 0.88–1.15 | 0.90 | 0.89 | 0.74–1.08 | 0.25 | 1.18 | 1.00–1.39 | 0.05 |
| + demographics, health | 1.05 | 0.91–1.21 | 0.52 | 0.91 | 0.73–1.13 | 0.41 | 1.23 | 1.03–1.46 | 0.02 |
| behaviors, comorbidities/labsa | |||||||||
| above + time dependent systolic | 1.05 | 0.91–1.22 | 0.50 | 0.92 | 0.74–1.14 | 0.43 | 1.23 | 1.03–1.47 | 0.02 |
| BP and stroke | |||||||||
| All above + other HTN med | 1.01 | 0.87–1.18 | 0.86 | 0.88 | 0.70–1.09 | 0.24 | 1.20 | 1.00–1.43 | 0.05 |
a
age, sex, race, education, income, smoking, alcohol use, diabetes, coronary artery disease, serum creatinine, serum low density lipoprotein, 3MSE score, and time dependent depression scores